EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

In vitro activity of apramycin (EBL-1003) in combination with colistin, meropenem, minocycline or sulbactam against XDR/PDR Acinetobacter baumannii isolates from Greece

I Galani iD, M Souli iD, D Katsala, I Karaiskos iD, H Giamarellou iD, A Antoniadou iD

Journal of Antimicrobial Chemotherapy · 2024

DOI: 10.1093/jac/dkae077 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Antimicrobial Chemotherapy, 2024. Verfasst von I Galani und 5 weiteren Autor:innen. Beteiligte Einrichtung: Infectious Diseases Laboratory, 4th Department of Internal Medicine, National and Kapodistrian University of Athens, School of Medicine, University G…. Hauptthemen laut MEDLINE: Acinetobacter baumannii, Anti-Bacterial Agents, Microbial Sensitivity Tests, Acinetobacter Infections. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

To evaluate the in vitro activity of the combination of apramycin with colistin, meropenem, minocycline or sulbactam, against some well-characterized XDR Acinetobacter baumannii clinical isolates from Greece, to understand how apramycin can be best incorporated into clinical practice and optimize effectiveness.

Methods

In vitro interactions of apramycin (0.5×, 1× and 2× the MIC value) with colistin (2 mg/L), meropenem (30 mg/L), minocycline (3.5 mg/L) or sulbactam (24 mg/L) were tested using time–kill methodology. Twenty-one clinical A. baumannii isolates were chosen, exhibiting apramycin MICs of 4–16 mg/L, which were at or below the apramycin preliminary epidemiological cut-off value of 16 mg/L. These isolates were selected for a range of colistin (4–32 mg/L), meropenem (16–256 mg/L), minocycline (8–32 mg/L) and sulbactam (8–32 mg/L) MICs across the resistant range. Synergy was defined as a ≥2 log10 cfu/mL reduction compared with the most active agent.

Results

The combination of apramycin with colistin, meropenem, minocycline or sulbactam was synergistic, at least at one of the concentrations of apramycin (0.5×, 1× or 2× MIC), against 83.3%, 90.5%, 90.9% or 92.3% of the tested isolates, respectively. Apramycin alone was bactericidal at 24 h against 9.5% and 33.3% of the tested isolates at concentrations equal to 1× and 2× MIC, while the combination of apramycin at 2× MIC with colistin, meropenem or sulbactam was bactericidal against all isolates tested (100%). The apramycin 2× MIC/minocycline combination had bactericidal activity against 90.9% of the tested isolates.

Conclusions

Apramycin combinations may have potential as a treatment option for XDR/pandrug-resistant (PDR) A. baumannii infections and warrant validation in the clinical setting, when this new aminoglycoside is available for clinical use.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Acinetobacter baumanniiAnti-Bacterial AgentsMicrobial Sensitivity TestsAcinetobacter InfectionsNebramycinGreeceHumansSulbactamDrug SynergismMeropenemColistinDrug Resistance, Multiple, BacterialMicrobial ViabilityMinocycline

Substanzen

Anti-Bacterial AgentsNebramycinapramycinSulbactamMeropenemColistinMinocycline

Autor:innen und Institutionen

  • Infectious Diseases Laboratory, 4th Department of Internal Medicine, National and Kapodistrian University of Athens, School of Medicine, University General Hospital 'ATTIKON', Rimini 1, 124 62 Chaidari, Athens, Greece.
  • Duke Clinical Research Institute, Duke University Medical Center, Durham, NC, USA.
  • 1st Department of Internal Medicine & Infectious Diseases, Hygeia General Hospital, Athens, Greece.
  • University of Cyprus, Medical School, Nicosia, Cyprus.

ORCID-Profile: I Galani, M Souli, I Karaiskos, H Giamarellou, A Antoniadou

Zitieren

APA

Galani, I., Souli, M., Katsala, D., Karaiskos, I., Giamarellou, H., & Antoniadou, A. (2024). In vitro activity of apramycin (EBL-1003) in combination with colistin, meropenem, minocycline or sulbactam against XDR/PDR Acinetobacter baumannii isolates from Greece. Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkae077

Vancouver

Galani I, Souli M, Katsala D, Karaiskos I, Giamarellou H, Antoniadou A. In vitro activity of apramycin (EBL-1003) in combination with colistin, meropenem, minocycline or sulbactam against XDR/PDR Acinetobacter baumannii isolates from Greece. Journal of Antimicrobial Chemotherapy. 2024. doi:10.1093/jac/dkae077

BibTeX
@article{Galani2024,
  author = {Galani, I and Souli, M and Katsala, D and Karaiskos, I and Giamarellou, H and Antoniadou, A},
  title = {In vitro activity of apramycin (EBL-1003) in combination with colistin, meropenem, minocycline or sulbactam against XDR/PDR Acinetobacter baumannii isolates from Greece},
  journal = {Journal of Antimicrobial Chemotherapy},
  year = {2024},
  doi = {10.1093/jac/dkae077}
}
Kostenlos starten →